known as allergan plc. for the company which was acquired by actavis plc see allergan inc. allergan plc type public traded as nyse agn s & p 500 component industry branded and generic pharmaceuticals and pharmaceutical research and development . founded est 2015 through the acquisition of allergan inc by actavis plc founder allen chao ph.d. and david hsia ph.d. headquarters dublin ireland and parsippany troy hills new jersey united states . number of locations 40 manufacturing facilities 27 global r & d centers and marketing sales facilities worldwide . area served 100 countries key people paul bisaro executive chairman brenton l. saunders president and ceo products branded and generic pharmaceuticals revenue us 15.07 billion 2015 1 operating income us 1.090 billion 2014 net income us 1.630 billion 2014 total assets us 52.529 billion 2014 total equity us 28.3355 billion 2014 number of employees 30 000 june 2015 website www.allergan.com on february 18 2015 the company formerly known as actavis plc announced its intention to change its name to allergan plc. this was completed as of june 15 2015 . actavis plc then became actavis which now forms the american generics division of the company . 2 3 contents 1 corporate history 1.1 2015 1.1.1 abandoned pfizer merger 1.1.2 2016 post pfizer 2 company evolution 2.1 allergan inc acquisition and actavis plc name change 3 key products 4 references 5 external links corporate history edit 2015 edit after the acquisition of allergan inc by actavis plc the new company made its first acquisition on july 6 when the company acquired start up oculeve for 125 million . 4 on july 7 the company announced it would acquire merck & cos late stage cgrp migraine portfolio as well as two experimental drugs mk 1602 and mk 8031 for 250 million . 5 in july allergan agreed to sell off its small molecule generic drug business actavis to teva pharmaceutical industries for 40.5 billion 33.75 billion in cash and 6.75 billion worth of shares 6 7 8 a transaction to be completed in q1 2016 . 9 a day later the company announced it would acquire naurex inc for 560 million with more tied to regulatory milestones . 10 11 in september the company announced it would acquire ophthalmic device start up aquesys for 300 million plus future sums tied to approval sales milestones . 12 in november the company acquired aesthetic device company northwood medical innovation . 13 two days after announcing the record breaking deal with pfizer the company announced it would partner with rugen therapeutic to develop new therapies for autism spectrum disorder and obsessive compulsive disorder . 14 abandoned pfizer merger edit main article pfizer allergan in late october 2015 the wall street journal reported that merger talks between allergan and pfizer were in early phases with pfizer approaching allergan due to an industry wide drop in share prices . any merger with allergan would then also give pfizer the ability to re domicile to ireland taking advantage of its lower tax rates . 15 16 on 23 november 2015 the two companies announced their intention to merge for an approximate sum of 160 billion making this the largest pharmaceutical deal ever and the third largest merger in history . as part of the deal pfizer ceo ian read would have remained ceo and chairman of the combined company to be called pfizer plc with allergan ceo brent saunders becoming president and chief operating officer . as part of the deal allergan shareholders will receive 11.3 shares of the company with pfizer shareholders receiving one . 17 pfizer discontinued the acquisition on 5 april 2016 after the obama administration announced its plan to move ahead with a resolution banning this form of tax avoidance known as a tax inversion . pfizer will pay allergan a breakup fee of 150 million . 18 2016 post pfizer edit in april the company announced it would join heptares therapeutics in a deal valued up to 3.3 billion collaborating on the development of a subtype selective muscarinic receptor agonists for alzheimer s disease and other major neurological disorders . 19 later in the same month the company announced it would acquire topokine therapeutics for 85 million plus undisclosed milestone payments gaining the phase iib iii compound xaf5 a potential first in class treatment for steatoblepharon or bags under the eyes . 20 in august 2016 teva after completing the 39 billion acquisition of actavis generics announced another smaller deal with allergan agreeing to acquire its generic distribution business anda for 500 million . 21 in august the company acquired forsight vision5 for more than 95 million expanding allergans offering in eye care . 22 in september the company announced it would acquire retrosense therapeutics for more than 60 million gaining the positive photosensitivity gene therapy treatment rst 001 . rst 100 is to be used in retinas in which rod and cone photoreceptors have degenerated over time causing in increase in the sensitivity of light hitting the retina . 23 later in the same month the company announced it would acquire vitae pharmaceuticals inc. for 21 per share 639 million in total 24 boosting the company s dermatology pipeline 25 26 tobira therapeutics for 1.695 billion and a day later akarna therapeutics for 50 million . 27 the two latter acqusitions aimed at boosting allergans liver disease portfolio . 28 company evolution edit allergan inc acquisition and actavis plc name change edit in november 2014 actavis plc announced its intention to acquire allergan inc the manufacturer of botox 29 completion of the deal would increase its market capitalization to 147 billion . 30 31 on march 17 2015 actavis plc completed the acquisition of allergan inc in a cash and equity transaction valued at approximately 70.5 billion . the combination created a 23 billion diversified global pharmaceutical company with commercial reach across 100 countries . in june 2015 actavis plc officially changed its name to allergan plc. 32 allergan plc formerly known as actavis until june 2015 when it adopted allergans name . actavis plc auden mckenzie holdings limited acq 2015 durata therapeutics acq 2014 forest laboratories acq 2014 aptalis pharma axcan pharma eurand pharmaceuticals furiex pharmaceuticals inc acq 2014 galen acq 2013 warner chilcott plc acq 2000 procter & gamble s prescription drug unit acq 2009 watson pharmaceuticals andrx corporation acq 2006 arrow group acq 2009 eden biodesign specifar pharmaceuticals s.a. acq 2011 ascent pharmahealth ltd acq 2012 actavis group acq 2012 allergan inc kythera biopharmaceuticals acq 2015 map pharmaceuticals inc acq 2013 inamed corporation acq 2006 allergan advanced medical optics spun off in 2006 janssen ortho spun off in 2006 abbott laboratories acq 2007 actavis generics sold 2015 to teva pharmaceuticals naurex inc acq 2015 aquesys acq 2015 topokine therapeutics acq 2016 anda sold 2016 to teva pharmaceuticals forsight vision5 acq 2016 retrosense therapeutics acq 2016 vitae pharmaceuticals inc acq 2016 tobira therapeutics acq 2016 akarna therapeutics acq 2016 key products edit actonel risedronic acid for the treatment or prevention osteoporosis and for paget s disease of bone treatment acuvail ketorolac ophthalmic solution for the treatment of pain and inflammation following cataract surgery aczone dapsone gel for acne alphagan p brimonidine ophthalmic solution for glaucoma androderm ciii testosterone transdermal system for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone asacol hd mesalamine extended release for moderately active ulcerative colitis atelvia risedronic acid delayed release for the treatment of osteoporosis in postmenopausal women avycaz ceftazidime avibactam for complicated intra abdominal infections in combination with metronidazole botox onabotulinumtoxina for various spasms and dystonias botox cosmetic vistabel onabotulinumtoxina an anti wrinkle cosmetic drug derived from botox bystolic nebivolol for hypertension combigan brimonidine timolol for glaucoma crinone progesterone gel for progesterone supplementation or replacement as part of an assisted reproductive technology art treatment for infertile women with progesterone deficiency dalvance dalbavancin for acute bacterial skin and skin structure infections absssi delzicol mesalamine extended release for mildly to moderately active ulcerative colitis doryx doxycycline hyclate extended release a tetracycline class antimicrobial enablex darifenacin extended release for overactive bladder estrace estradiol vaginal cream for vulvar and vaginal atrophy due to menopause fetzima levomilnacipran extended release for major depressive disorder gelnique oxybutynin gel for overactive bladder juv derm injectable gel cross linked hyaluronic acid a dermal filler kybella deoxycholic acid injection for double chin lastacaft alcaftadine ophthalmic solution for the prevention of itching associated with eye allergies latisse bimatoprost ophthalmic solution for hypotrichosis of the eyelashes liletta levonorgestrel releasing intrauterine system for contraception linzess linaclotide for irritable bowel syndrome with constipation ibs c and chronic idiopathic constipation co marketed with ironwood pharmaceuticals lo loestrin fe norethisterone and ethinyl estradiol ; ethinyl estradiol ; ferrous fumarate for contraception lumigan bimatoprost ophthalmic solution for glaucoma namenda memantine for moderate to severe dementia of the alzheimer s type namenda xr memantine extended release for moderate to severe alzheimer s disease namzaric memantine extended release donepezil for moderate to severe alzheimer s disease in patients who are currently taking and can continue to take certain doses of both namenda or namenda xr see above and donepezil natrelle breast implants silicone and saline ozurdex dexamethasone intravitreal implant for branch retinal vein occlusion brvo and central retinal vein occlusion crvo orbera system an intragastric balloon inserted endoscopically ; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index bmi of 27 or greater rapaflo silodosin for benign prostatic hyperplasia restasis ciclosporin ophthalmic emulsion for dry eye syndrome saphris asenapine sublingual tablets for schizophrenia and bipolar i disorder skinmedica for facial lines tazorac tazarotene for acne and psoriasis . teflaro ceftaroline fosamil for community acquired bacterial pneumonia cabp and acute bacterial skin and skin structure infections absssi viberzi eluxadoline for diarrhea predominant irritable bowel syndrome ibs d viibryd vilazodone for major depressive disorder zenpep pancrelipase for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions . references edit thestreet transcripts . actavis act earnings report q1 2015 conference call transcript . the street . retrieved 27 november 2015 . calia michael 18 february 2015 . actavis adopting allergan name ; earnings soar as closing of deal looms . the wall street journal . retrieved 19 february 2015 . haggerty neil 15 june 2015 . actavis changes name to allergan after deal for botox maker . the wall street journal . retrieved 15 june 2015 . garde damian 6 july 2015 . allergan bets 125m on a new approach to dry eye disease . fiercebiotech . retrieved 27 november 2015 . carroll john 7 july 2015 . updated bowing out of crowded race merck sells a migraine drug to allergan for 250m . fiercebiotech . retrieved 27 november 2015 . allergan accelerates transformation to branded growth pharma leader by divesting global generics business to teva for 40.5 billion . allergan . 27 july 2015 . retrieved 27 november 2015 . koons cynthia 27 july 2015 . teva ceo 40.5 billion allergan deal is just the beginning . bloomberg . retrieved 27 november 2015 . somayaji chitra 27 july 2015 . teva snaps up allergan s generics arm dumping mylan . bloomberg . retrieved 27 november 2015 . o donnell carl 3 december 2015 . teva divesting 1 billion in assets to clear allergan deal . reuters . retrieved 4 december 2015 via yahoo finance . carroll john 27 july 2015 . allergan joins the hunt for a transformational biotech deal . fiercebiotech . retrieved 27 november 2015 . carroll john 26 july 2015 . updated allergan bags nmda depression drugs in 560m plus naurex buyout . fiercebiotech . retrieved 27 november 2015 . lawrence stacy 4 september 2015 . allergan to grab aquesys for 300m to add minimally invasive glaucoma microshunt . fiercemedicaldevices . retrieved 27 november 2015 . saxena varun 5 november 2015 . allergan beefs up in aesthetics with implant purchase . does m & a suitor pfizer approve . fiercemedicaldevices